| Index | — | P/E | — | EPS (ttm) | -0.73 | Insider Own | 6.98% | Shs Outstand | 452.97M | Perf Week | -41.80% |
| Market Cap | 3.63B | Forward P/E | — | EPS next Y | -0.17 | Insider Trans | 0.00% | Shs Float | 394.26M | Perf Month | -43.60% |
| Enterprise Value | 3.38B | PEG | — | EPS next Q | -0.08 | Short Float | 14.95% | Perf Quarter | 83.94% | ||
| Income | -289.00M | P/S | 11.21 | EPS this Y | — | Short Ratio | 3.47 | Perf Half Y | 108.31% | ||
| Sales | 324.00M | P/B | 4.94 | EPS next Y | — | ROA | -31.62% | Short Interest | 58.93M | Perf YTD | 193.77% |
| Book/sh | 1.62 | P/C | 12.19 | EPS next 5Y | — | ROE | -40.51% | 52W High | 15.37 -47.82% | Perf Year | 311.28% |
| Cash/sh | 0.66 | P/FCF | — | EPS past 3/5Y | — | ROIC | -35.97% | 52W Low | 1.76 355.68% | Perf 3Y | 116.76% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 48.40% | Volatility | 9.75% 7.26% | Perf 5Y | -69.38% |
| Dividend TTM | — | EV/Sales | 10.43 | EPS Y/Y TTM | — | Oper. Margin | -91.14% | ATR (14) | 1.21 | Perf 10Y | 24.34% |
| Dividend Ex-Date | — | Quick Ratio | 3.82 | Sales Y/Y TTM | 33.88% | Profit Margin | -89.09% | RSI (14) | 29.13 | Recom | 2.29 |
| Dividend Gr. 3/5Y | — | Current Ratio | 4.34 | EPS Q/Q | 66.67% | SMA20 | -39.83% | Beta | 0.83 | Target Price | 13.44 |
| Payout | 0.00% | Debt/Eq | 0.06 | Sales Q/Q | 65.00% | SMA50 | -29.44% | Rel Volume | 1.20 | Prev Close | 8.48 |
| Employees | 975 | LT Debt/Eq | 0.06 | Earnings | Nov 05 | SMA200 | 36.73% | Avg Volume | 17.47M | Price | 8.02 |
| IPO Date | Oct 15, 2010 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 14.33% 13.07% | Net Debt/EBITDA | — | Volume | 21,019,909 | Change | -5.42% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-13-26 | Reiterated | Barclays | Overweight | $15 → $18 |
| Oct-08-26 | Reiterated | Robert W. Baird | $6.00 → $11 | |
| Sep-30-26 | Reiterated | Wells Fargo | Overweight | $5.00 → $18 |
| Sep-29-26 | Reiterated | Jefferies | $16 | |
| Sep-29-26 | Reiterated | HC Wainwright & Co. | Buy | $20 |
| Sep-24-26 | Resumed | Goldman Sachs | Buy | $2.00 → $15 |
| Sep-17-26 | Reiterated | Barclays | Overweight | $13 → $15 |
| Aug-20-26 | Reiterated | UBS | Neutral | $2.00 → $7.00 |
| Aug-18-26 | Reiterated | Mizuho | Outperform | $11 |
| Aug-07-26 | Reiterated | Robert W. Baird | $4.00 → $6.00 |
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 324 | 264 | 164 | 1 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 167 | 173 | 124 | 11 | — | — | — | — | — | |
| Gross Profit | 158 | 90 | 40 | -10 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 149 | 152 | 153 | 107 | — | — | — | — | — | |
| Research and Development | 267 | 300 | 282 | 344 | — | — | — | — | — | |
| Other Operating Expense | 38 | 37 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -296 | -398 | -395 | -461 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 2 | 5 | 20 | 13 | — | — | — | — | — | |
| Net Income Before Taxes | -295 | -393 | -375 | -448 | — | — | — | — | — | |
| Income Taxes | -4 | -2 | -3 | -3 | — | — | — | — | — | |
| Consolidated Net Income | -289 | -391 | -372 | -444 | — | — | — | — | — | |
| Net Income From Continuing Operations | -289 | -391 | -372 | -444 | — | — | — | — | — | |
| Net Income | -289 | -391 | -372 | -444 | — | — | — | — | — | |
| EPS (Recurring) | -0.73 | -1.09 | -1.28 | -1.89 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.73 | -1.09 | -1.28 | -1.89 | — | — | — | — | — | |
| EPS (Diluted) | -0.73 | -1.09 | -1.28 | -1.89 | — | — | — | — | — | |
| EBITDA | -252 | -351 | -331 | -414 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 11.14 | 3.69 | 13.09 | 1,910.55 | — | — | — | — | — | |
| Gross Margin | 48.77 | 34.09 | 24.39 | -1,000.00 | — | — | — | — | — | |
| Operating Margin | -91.36 | -150.76 | -240.85 | -46,100.00 | — | — | — | — | — | |
| Net Margin | -89.20 | -148.11 | -226.83 | -44,400.00 | — | — | — | — | — | |
| Shares Outstanding | 450 | 357 | 290 | 235 | — | — | — | — | — | |
| Market Capitalization | 3,609 | 975 | 2,146 | 1,911 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Puri Raj K. | Chief Regulatory Officer | Sep 08 '26 | Option Exercise | 0.00 | 9,766 | 0 | 260,842 | Sep 10 |
| Vogt Frederick G | Interim CEO & General Counsel | Sep 08 '26 | Option Exercise | 0.00 | 15,626 | 0 | 602,085 | Sep 10 |
| BILINSKY IGOR | Chief Operating Officer | Sep 08 '26 | Option Exercise | 0.00 | 7,813 | 0 | 146,050 | Sep 10 |
| Vogt Frederick G | Interim CEO & General Counsel | Sep 01 '26 | Option Exercise | 0.00 | 41,669 | 0 | 604,161 | Sep 03 |
| Puri Raj K. | Chief Regulatory Officer | Sep 01 '26 | Option Exercise | 0.00 | 5,470 | 0 | 253,584 | Sep 03 |
| BILINSKY IGOR | Chief Operating Officer | Sep 01 '26 | Option Exercise | 0.00 | 8,789 | 0 | 142,709 | Sep 03 |
| Kirby Daniel Gordon | Chief Commercial Officer | Aug 10 '26 | Option Exercise | 0.00 | 10,001 | 0 | 156,947 | Aug 12 |
| Roche Corleen M. | Chief Financial Officer | Aug 06 '26 | Option Exercise | 0.00 | 49,995 | 0 | 49,995 | Aug 10 |
| Vogt Frederick G | Interim CEO & General Counsel | Jun 05 '26 | Option Exercise | 0.00 | 15,625 | 0 | 569,130 | Jun 09 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Jun 05 '26 | Option Exercise | 0.00 | 7,813 | 0 | 144,087 | Jun 09 |
| Puri Raj K. | Chief Regulatory Officer | Jun 05 '26 | Option Exercise | 0.00 | 9,766 | 0 | 251,957 | Jun 09 |
| BILINSKY IGOR | Chief Operating Officer | Jun 05 '26 | Option Exercise | 0.00 | 7,813 | 0 | 137,896 | Jun 09 |
| Vogt Frederick G | Interim CEO & General Counsel | Jun 01 '26 | Option Exercise | 0.00 | 41,668 | 0 | 571,206 | Jun 03 |
| Puri Raj K. | Chief Regulatory Officer | Jun 01 '26 | Option Exercise | 0.00 | 5,469 | 0 | 244,699 | Jun 03 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Jun 01 '26 | Option Exercise | 0.00 | 8,790 | 0 | 140,747 | Jun 03 |